Highlight
1. SCG101 is an autologous T-cell therapy engineered to target HBV using a high-affinity natural T-cell receptor, specifically for HBV-related HCC.
2. In a first-in-human investigator-initiated trial, SCG101 showed profound T-cell expansion, rapid and substantial HBsAg reduction, and objective tumor responses in heavily pretreated patients.
3. Treatment-related toxicities including transient ALT elevation and cytokine release syndrome were manageable and non-dose-limiting.
4. Durable complete remission was observed in one patient, with ongoing progression-free survival at 27 months, highlighting potential for long-term disease control.
